HEALTHSOUTH Corp.

Jefferies reiterated Buy on HealthSouth Corporation (NYSE: HLS). At the same time, Jefferies raised its price target to $33 from $30. In a research report published today, Jefferies states, "We think HLS remains a compelling investment supported by favorable demographic trends, non-discretionary...

Morgan Keegan, citing a first quarter above estimates, is raising its price target from $29.25 to $32 and is maintaining its Outperform rating on HealthSouth Corp. (NYSE: HLS). Says Morgan Keegan, in the report, “HealthSouth reported stronger-than-expected first quarter earnings and announced, as...

Morgan Keegan is out with its report today on HealthSouth Corp. (NYSE: HLS), maintaining Outperform. In a note to clients, Morgan Keegan writes, "We believe HealthSouth is positioned to generate strong free cash flow, driving share price appreciation. In the near term, we expect the drivers to be...

Jefferies & Company published a health care update today as 47% of their covered companies guidance was maintained or in line with the street. Jefferies & Co. think management teams are taking a more cautious and realistic approach because of "2010's soft utilization trends, HC reform and...